Down syndrome and Alzheimer's disease: A scoping review of functional performance and fall risk

被引:2
|
作者
Washington, Selena E. [1 ]
Cler, Emily [1 ]
Lowery, Cameron [2 ]
Stark, Susan L. [3 ]
机构
[1] St Louis Univ, Dept Occupat Sci & Occupat Therapy, St Louis, MO USA
[2] Harris Stowe State Univ, Dept Biol, St Louis, MO USA
[3] Washington Univ, Sch Med St Louis, PrograminOccupat Therapy, St Louis, MO USA
关键词
aging; cognition; Down syndrome; falls; function; BRAIN AMYLOID-BETA; ADULTS; ACCUMULATION; DEMENTIA;
D O I
10.1002/trc2.12393
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Alzheimer's disease (AD) occurs in aging adults with Down syndrome (DS) at a higher prevalence and an earlier age than in typical aging adults. As with the general aging adult population, there is an urgent need to understand the preclinical and early phases of AD progression in the adult population with DS. The aim of this scoping review was to synthesize the current state of the evidence and identify gaps in the literature regarding functional activity performance and falls and their significance to disease staging (i.e., mild, moderate, and severe defined staging criteria) in relation to Alzheimer's disease and related dementias (ADRD) in adults with DS. Methods: This scoping review included six electronic databases (e.g., PsycInfo, Academic Search Complete, CINAHL, COCHRANE Library, MEDLINE, and PubMed). Eligible studies included participants with DS >= 25 years of age, studies with functional measures and/or outcomes (e.g., activities of daily living, balance, gait, motor control, speech, behavior, and cognition; falls; and fall risks), and studies that investigated AD pathology and implications. Results: Fourteen eligible studies were included and categorized through a thematic analysis into the following themes: (1) physical activity and motor coordination (PAMC), (2) cognition, (3) behavior, and (4) sleep. The studies indicated how functional activity performance and engagement may contribute to early identification of those at risk of cognitive decline and AD development and/or progression. Discussion: There is a need to expand the research regarding ADRD pathology relative to functional outcomes in adults with DS. Functional measures related to disease staging and cognitive impairment are essential to understanding how AD progression is characterized within real-world settings. This scoping review identified the need for additionalmixed-methods research to examine the use of assessment and intervention related to function and its detection of cognitive decline and AD progression.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Blood Biomarkers for Alzheimer's Disease in Down Syndrome
    Montoliu-Gaya, Laia
    Strydom, Andre
    Blennow, Kaj
    Zetterberg, Henrik
    Ashton, Nicholas James
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [32] Alzheimer's disease and down syndrome: Response to donepezil
    Lott, IT
    Osann, K
    Doran, E
    Nelson, L
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S73 - S73
  • [33] Weight Loss and Alzheimer's Disease in Down Syndrome
    Fleming, Victoria
    Helsel, Brian C.
    Ptomey, Lauren T.
    Rosas, H. Diana
    Handen, Benjamin
    Laymon, Charles
    Christian, Bradley T.
    Head, Elizabeth
    Mapstone, Mark
    Lai, Florence
    Krinsky-McHale, Sharon
    Zaman, Shahid
    Ances, Beau M.
    Lee, Joseph H.
    Hartley, Sigan L.
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 91 (03) : 1215 - 1227
  • [34] Down Syndrome and Alzheimer's Disease: Biological correlates
    Torr, Jennifer
    JOURNAL OF INTELLECTUAL & DEVELOPMENTAL DISABILITY, 2007, 32 (03): : 228 - 228
  • [35] The Search for Biomarkers of Alzheimer's Disease in Down Syndrome
    Handen, Benjamin L.
    AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2020, 125 (02): : 97 - 99
  • [36] Identification of Alzheimer's disease in adults with Down syndrome
    Torr, Jennifer
    Iacono, Teresa
    JOURNAL OF POLICY AND PRACTICE IN INTELLECTUAL DISABILITIES, 2008, 5 (01) : 31 - 31
  • [37] Dissecting the Alzheimer's disease phenotype of Down syndrome
    Strydom, A.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2016, 60 (7-8) : 743 - 743
  • [38] Diagnostic biomarkers of Alzheimer's disease in Down syndrome
    Rafii, Michael S.
    LANCET NEUROLOGY, 2018, 17 (10): : 831 - 832
  • [39] Complement dysregulation and Alzheimer's disease in Down syndrome
    Veteleanu, Aurora
    Pape, Sarah
    Davies, Kate
    Kodosaki, Eleftheria
    Hye, Abdul
    Zelek, Wioleta M.
    Strydom, Andre
    Morgan, B. Paul
    ALZHEIMERS & DEMENTIA, 2023, 19 (04) : 1383 - 1392
  • [40] Alzheimer's disease in older individuals with Down syndrome
    Strydom, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S113 - S114